2-amino-5-hydroxy-4-oxopentanoic acid: isolated from Streptomyces
ID Source | ID |
---|---|
PubMed CID | 10219513 |
SCHEMBL ID | 10618897 |
MeSH ID | M0162473 |
Synonym |
---|
levulinic acid, 2-amino-5-hydroxy- |
5-hydroxy-4-oxo-norvaline |
h-899 |
pentanoic acid, 2-amino-5-hydroxy-4-oxo- |
norvaline, 5-hydroxy-4-oxo- |
2-amino-5-hydroxylevulinic acid |
2-amino-5-hydroxy-4-oxopentanoic acid |
4439-84-3 |
AKOS006278971 |
unii-gw5bbj7dqw |
gw5bbj7dqw , |
SCHEMBL10618897 |
2-amino-4-oxo-5-hydroxypentanoic acid |
5-hydroxy-4-oxonorvaline, dl- |
dl-hon |
hon racemate [mi] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (10.00) | 18.7374 |
1990's | 7 (35.00) | 18.2507 |
2000's | 4 (20.00) | 29.6817 |
2010's | 6 (30.00) | 24.3611 |
2020's | 1 (5.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (9.52%) | 6.00% |
Case Studies | 2 (9.52%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 17 (80.95%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Substance | Relationship Strength | Studies | Trials | Classes | Roles |
---|---|---|---|---|---|
aminolevulinic acid Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp. | 5.97 | 20 | 0 | 4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid | antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite |
nitrates Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical. | 1.98 | 1 | 0 | monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species | |
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid. | 2.68 | 3 | 0 | aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid | Escherichia coli metabolite; mouse metabolite; neurotransmitter |
homoserine homoserine : An alpha-amino acid that is glycine substituted at the alpha-position by a 2-hydroxyethyl group.. L-homoserine : The L-enantiomer of homoserine. | 1.97 | 1 | 0 | amino acid zwitterion; homoserine | algal metabolite; Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite |
buthionine sulfoximine Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7). 2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.. S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl. | 2 | 1 | 0 | diastereoisomeric mixture; homocysteines; non-proteinogenic alpha-amino acid; sulfoximide | EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer |
magnesium sulfate Magnesium Sulfate: A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083). magnesium sulfate : A magnesium salt having sulfate as the counterion. | 1.98 | 1 | 0 | magnesium salt; metal sulfate; organic magnesium salt | anaesthetic; analgesic; anti-arrhythmia drug; anticonvulsant; calcium channel blocker; cardiovascular drug; fertilizer; tocolytic agent |
potassium nitrate potassium nitrate: RN given refers to cpd with MF of K-HNO3; when combined with charcoal and sulfur it can form EXPLOSIVE AGENTS. potassium nitrate : The inorganic nitrate salt of potassium. | 1.98 | 1 | 0 | inorganic nitrate salt; potassium salt | fertilizer |
azoxybacilin azoxybacilin: an azoxy-containing antibiotic; produced by Bacillus cereus; structure given in first source. azoxybacilin : A non-proteinogenic alpha-amino acid that is (2S)-2-aminobutanoic acid substituted by a (Z)-methyl-NNO-azoxy moiety at position 4. It is an antibiotic isolated from the culture broth of Bacillus cereus and exhibits antifungal activity. | 2.01 | 1 | 0 | ||
aflatoxin b1 Aflatoxin B1: A potent hepatotoxic and hepatocarcinogenic mycotoxin produced by the Aspergillus flavus group of fungi. It is also mutagenic, teratogenic, and causes immunosuppression in animals. It is found as a contaminant in peanuts, cottonseed meal, corn, and other grains. The mycotoxin requires epoxidation to aflatoxin B1 2,3-oxide for activation. Microsomal monooxygenases biotransform the toxin to the less toxic metabolites aflatoxin M1 and Q1.. aflatoxin B1 : An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11. | 2.05 | 1 | 0 | aflatoxin; aromatic ether; aromatic ketone | carcinogenic agent; human metabolite |
rhizocticin a rhizocticin A: isolated from Bacillus subtilis ATCC 6633; structure given in first source | 2.01 | 1 | 0 | peptide | |
nad NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety. | 2.01 | 1 | 0 | organophosphate oxoanion | cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite |
Condition | Indicated | Relationship Strength | Studies | Trials |
---|---|---|---|---|
Angiospasm, Intracranial [description not available] | 0 | 3.23 | 1 | 0 |
Kidney Failure A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. | 0 | 3.23 | 1 | 0 |
Leukoencephalopathy Syndrome, Posterior [description not available] | 0 | 3.23 | 1 | 0 |
2019 Novel Coronavirus Disease [description not available] | 0 | 3.23 | 1 | 0 |
HbS Disease [description not available] | 0 | 3.23 | 1 | 0 |
Autoimmune Disease [description not available] | 0 | 3.23 | 1 | 0 |
Brain Swelling [description not available] | 0 | 3.23 | 1 | 0 |
Bilateral Headache [description not available] | 0 | 3.23 | 1 | 0 |
Blood Pressure, High [description not available] | 0 | 3.23 | 1 | 0 |
Edema-Proteinuria-Hypertension Gestosis [description not available] | 0 | 3.23 | 1 | 0 |
Absence Seizure [description not available] | 0 | 3.23 | 1 | 0 |
Day Blindness [description not available] | 0 | 3.23 | 1 | 0 |
Anemia, Sickle Cell A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S. | 0 | 3.23 | 1 | 0 |
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. | 0 | 3.23 | 1 | 0 |
Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6) | 0 | 3.23 | 1 | 0 |
Eclampsia Onset of HYPERREFLEXIA; SEIZURES; or COMA in a previously diagnosed pre-eclamptic patient (PRE-ECLAMPSIA). | 0 | 3.23 | 1 | 0 |
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS. | 0 | 3.23 | 1 | 0 |
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. | 0 | 3.23 | 1 | 0 |
Pre-Eclampsia A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease. | 0 | 3.23 | 1 | 0 |
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. | 0 | 3.23 | 1 | 0 |
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder. | 0 | 3.23 | 1 | 0 |
Vasospasm, Intracranial Constriction of arteries in the SKULL due to sudden, sharp, and often persistent smooth muscle contraction in blood vessels. Intracranial vasospasm results in reduced vessel lumen caliber, restricted blood flow to the brain, and BRAIN ISCHEMIA that may lead to hypoxic-ischemic brain injury (HYPOXIA-ISCHEMIA, BRAIN). | 0 | 3.23 | 1 | 0 |
Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE. | 0 | 3.23 | 1 | 0 |
Acute Chest Syndrome Respiratory syndrome characterized by the appearance of a new pulmonary infiltrate on chest x-ray, accompanied by symptoms of fever, cough, chest pain, tachypnea, or DYSPNEA, often seen in patients with SICKLE CELL ANEMIA. Multiple factors (e.g., infection, and pulmonary FAT EMBOLISM) may contribute to the development of the syndrome. | 0 | 3.23 | 1 | 0 |
Foreign Bodies Inanimate objects that become enclosed in the body. | 0 | 2.15 | 1 | 0 |
Bacterial Disease [description not available] | 0 | 2.08 | 1 | 0 |
Tick Infestations Infestations with soft-bodied (Argasidae) or hard-bodied (Ixodidae) ticks. | 0 | 2.08 | 1 | 0 |
Bacterial Infections Infections by bacteria, general or unspecified. | 0 | 2.08 | 1 | 0 |
Genetic Predisposition [description not available] | 0 | 2.48 | 2 | 0 |
Rheumatoid Arthritis [description not available] | 0 | 2.11 | 1 | 0 |
Alcohol Drinking Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking. | 0 | 2.11 | 1 | 0 |
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. | 0 | 2.11 | 1 | 0 |
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) | 0 | 2.05 | 1 | 0 |
Lassa Virus Infection [description not available] | 0 | 3.03 | 1 | 0 |
Zoonoses Diseases of non-human animals that may be transmitted to HUMANS or may be transmitted from humans to non-human animals. | 0 | 3.03 | 1 | 0 |
Lassa Fever An acute febrile human disease caused by the LASSA VIRUS. | 0 | 3.03 | 1 | 0 |
Actinic Keratosis [description not available] | 0 | 2.04 | 1 | 0 |
Carcinoma, Basal Cell, Pigmented [description not available] | 0 | 2.04 | 1 | 0 |
Carcinoma, Epidermoid [description not available] | 0 | 2.04 | 1 | 0 |
Condition, Preneoplastic [description not available] | 0 | 2.04 | 1 | 0 |
Cancer of Skin [description not available] | 0 | 2.04 | 1 | 0 |
Extra-Mammary Paget Disease [description not available] | 0 | 2.04 | 1 | 0 |
Erythroplasia A condition of the mucous membrane characterized by erythematous papular lesions. | 0 | 2.04 | 1 | 0 |
Carcinoma, Basal Cell A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471) | 0 | 2.04 | 1 | 0 |
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) | 0 | 2.04 | 1 | 0 |
Paget Disease, Extramammary A rare cutaneous neoplasm that occurs in the elderly. It develops more frequently in women and predominantly involves apocrine gland-bearing areas, especially the vulva, scrotum, and perianal areas. The lesions develop as erythematous scaly patches that progress to crusted, pruritic, erythematous plaques. The clinical differential diagnosis includes squamous cell carcinoma in situ and superficial fungal infection. It is generally thought to be an adenocarcinoma of the epidermis, from which it extends into the contiguous epithelium of hair follicles and eccrine sweat ducts. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1478) | 0 | 2.04 | 1 | 0 |
Precancerous Conditions Pathological conditions that tend eventually to become malignant. | 0 | 2.04 | 1 | 0 |
Skin Neoplasms Tumors or cancer of the SKIN. | 0 | 2.04 | 1 | 0 |
Keratosis, Actinic White or pink lesions on the arms, hands, face, or scalp that arise from sun-induced DNA DAMAGE to KERATINOCYTES in exposed areas. They are considered precursor lesions to superficial SQUAMOUS CELL CARCINOMA. | 0 | 2.04 | 1 | 0 |
Biliary Calculi [description not available] | 0 | 2.05 | 1 | 0 |
Cancer of Gallbladder [description not available] | 0 | 2.05 | 1 | 0 |
Gallbladder Neoplasms Tumors or cancer of the gallbladder. | 0 | 2.05 | 1 | 0 |
Gallstones Solid crystalline precipitates in the BILIARY TRACT, usually formed in the GALLBLADDER, resulting in the condition of CHOLELITHIASIS. Gallstones, derived from the BILE, consist mainly of calcium, cholesterol, or bilirubin. | 0 | 2.05 | 1 | 0 |
Cancer of Ovary [description not available] | 0 | 2 | 1 | 0 |
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. | 0 | 2 | 1 | 0 |